TAG:
testing for breast cancer
Two Omaha Med Centers Form Collaborative Lab
CEO SUMMARY: An accountable care organization with a strong clinical laboratory component is taking shape in Nebraska. The University of Nebraska Medical Center has developed a partnership with the Nebraska Methodist Health System to form an ACO called the Accountable Car…
July 05, 2011 “Intelligence: Late Breaking Lab News”
Two laboratory companies based in Spokane, Washington, were recently recognized in a list of Washington State’s “100 Best Companies to Work For” in 2011. One was Incyte Pathology, Inc., an anatomic pathology group. The other was Pathology Associates Medical Laboratori…
Momentum Continues for Digital Pathology
CEO SUMMARY: Last month, digital imaging in pathology gained additional momentum with the latest FDA clearance. Aperio Technologies, Inc., now has FDA clearance to market its slide scanning system for reading digital progesterone receptor (PR) slides on a computer monitor. Aperio plans to…
New Technologies Bring New Issues for Pathologists
TECHNOLOGICAL IMPROVEMENTS ARE MOVING through the lab industry like a buzz saw through balsa. Three briefings in this issue provide examples. In two briefings, we address the topic of false positive results generated in part because of innovations in molecular testing. In the third briefing, we expla…
New Rules to Boost Cancer Test Accuracy
CEO SUMMARY: Recent developments in breast cancer testing are leading to changes in pathology. Oncologists and pathologists have issued new guidelines regarding HER2 testing and new research suggests changes may be coming for estrogen-receptor testing as well. For the first time, the new …
Developing Technology Expected To Fuel Boom In Anatomic Pathology
CEO SUMMARY: Established demographic trends point to a coming boom in the demand for anatomic pathology services. Greater number s of senior citizens, living longer lives, will raise the number of cancer cases diagnosed annually in the United States. New diagnostic technology will increas…
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.